INTRODUCTION
Cancer is an independent and major risk factor for venous thromboembolism (VTE), 1, 2 comprising deep vein thrombosis (DVT) and pulmonary embolism (PE). Of all first VTE events 20-30% are malignancy-associated and VTE is the second leading cause of death in patients with malignancy. 3, 4 Anticoagulation therapy in cancer patients remains challenging with high recurrence rates of VTE and increased rates of anticoagulant-related bleeding. Currently used anticoagulants such as low molecular weight heparin (LMWH) and vitamin K antagonists (VKAs), target enzymes of the coagulation cascade that are critical for fibrin formation. As a result, treatment of VTE carries an inherent risk of potentially life-threatening bleeding. 5 Prostate cancer (PC) is the second most common cancer in men and ranks 6 th in malignancy-related mortality. 6, 7 Although the incidence of approximately 13 malignancyassociated VTE cases per 1000 person-year is not particularly high in PC patients 7 due to the high prevalence of the disease, concurrence of VTE and PC presents a major medical burden.
Fibrin formation is initiated in plasma by two distinct mechanisms, termed the extrinsic and intrinsic coagulation pathways. The extrinsic coagulation pathway is initiated by binding of circulating coagulation factor VII/VIIa to the transmembrane protein tissue factor (TF). 8 In contrast, the intrinsic pathway of coagulation is triggered by contact-induced autoactivation of zymogen factor XII (FXII), resulting in the active protease FXIIa. FXIIa leads to fibrin formation via its substrate factor XI (FXI). 9 Ablation of F12 and F11 genes protects mice from DVT 10 and PE 11 and inherited deficiency in FXI reduces the incidence of DVT in patients. 12 Although targeting FXII interferes with thrombus formation in non-human primates, 13 there is a lack in epidemiological studies that analyzed protection from thromboembolic disease in individuals with severe FXII deficiency. 9 Despite its crucial importance for thrombosis in animal models, FXII is dispensable in hemostasis (cessation of bleeding at sites of injury) and FXII deficient humans and mice have a normal hemostatic capacity. 9 Procoagulant platelet-released polyphosphate (polyP) activates FXII in vitro 14 with implications for thrombosis in vivo. 15 PolyP is a linear, unbranched polymer of orthophosphate residues linked by phosphoanhydride bonds. The polymer is ubiquitously found in nature and varies in chain length from a few phosphate units to several thousands. 16 The principle fibrin forming mechanism underlying cancer-associated thrombosis is considered to be up-regulation of TF expression on cancer cells and cancer cell-derived membrane vesicles. Indeed, clinical and experimental studies revealed largely increased TF antigen on PC cells and secreted exosomes (prostasomes), 17 in tumor tissue and in plasma samples of PC patients, which was associated with excess activity of the extrinsic coagulation pathway. 18 Prostasomes released from large intracellular storage vesicles of prostate epithelial cells were originally described in seminal fluid 19 and are procoagulant in plasma. 17 Prostasomes share cholesterol-and sphingomyelin-rich plasma membranes 20 with other exosomes secreted by pancreatic, breast or colon adenocarcinoma cells.
21,22
Here, we identify a novel and unexpected role of the polyP/FXII-driven intrinsic pathway of coagulation in PC-associated thrombosis. Coagulation analyses of patient plasma and PE models in genetically altered mice show that PC cells and prostasomes expose long chain polyP on their surface. The polymer activates FXII, triggers clotting in PC patient plasma and causes thrombosis in mice. Interference with the polyP/FXII pathway provides protection from thrombosis while not increasing bleeding risk. These data identify a new coagulation mechanism that contributes to PC-driven thrombosis and suggest that interference with the polyP/FXII axis constitutes a novel target for anticoagulant drug development in PC-related thrombosis without impairing hemostasis.
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METHODS

Prostasome-induced pulmonary thromboembolism
Mice were anesthetized by intraperitoneal (i.p.) injection of 2,2,2-tribromoethanol and 2-methyl-2-butanol. PC3 cell-[ATCC: CRL-1435; 0.8 µg/g body weight (bw)], seminal-(10 µg/g bw) or patient-derived prostasomes (150 µg/g bw) were mixed with epinephrine (0.06 µg/g bw) and slowly injected into the inferior vena cava. In some experiments, mice were injected intravenously (i.v.) with active site inhibited factor VII (ASIS; 2.5 µg/g bw), 3F7 (4.5 µg/g bw), polyP-binding domain (PPBD) of Escherichia coli (E. coli) exophosphatase (EC number 3.6.1.11; 150 µg/g bw) or saline 10 min before challenge. None of these inhibitors increased bleeding. Lung perfusion, 23 bleeding time and loss of hemoglobin assays were previously described.
24 Systemic blood pressure was measured by volume pressure recording of the tail, using the CODA non-invasive blood pressure system (Kent Scientific Corp., Torrington, CT, USA).
Supplemental methods
Detailed methods describing study design, blood collection, animals, cell culture, prostasome/exosome isolation, extraction of polyP, electron microscopy, expression of PPBD, ELISA for polyP detection, staining of polyP, immunofluorescence, real-time thrombin generation analysis, recalcification time and activation of FXII, histological analysis, and data analysis are available in the Supplemental Methods section on the Blood website.
RESULTS
Prostasomes initiate pulmonary embolism via the intrinsic pathway of coagulation
To analyze the functions of prostasomes in venous thrombosis, we challenged mice in a model of lethal PE by infusion of human PC cell (PC3)-derived prostasomes into the inferior vena cava. Mice that survived the challenge >30 minutes were considered survivors. A single animal out of 15 wild-type (WT) mice survived prostasome injection (Fig. 1A) (Fig. 1E) . As cell culture-derived prostasomes might differ from those generated in vivo, we isolated prostasomes from human seminal fluid 19 and analyzed them in our PE model. Infusion of seminal prostasomes induced lethal PE in 5/6 WT mice (Fig.  1F) . In contrast, F12 -/-(4/6 survived), F11 -/-(4/6 survived) and ASIS-treated WT (3/6 survived) mice were largely protected from seminal prostasome-triggered thrombotic challenge (P< 0.05 vs. WT, each). Consistently, prostasomes isolated from PC patient plasma also induced lethal PE in WT mice (0/5 survived, P< .01; Fig. 1G ). In contrast, all WT mice (5/5) survived challenge with exosomes isolated from healthy men.
Prostasomes trigger FXII-mediated thrombin and fibrin formation in vitro
We characterized human seminal-and PC3 cell culture-derived prostasomes using transmission electron microscopy (TEM). Both seminal-( Fig. 2A) and cell culture- (Fig. 2D) prostasomes appeared as cup-shaped vesicles due to dehydration. The particles shared a similar size distribution with minimal and maximal diameter of 30 and 400 nm [Figs. 2B (seminal) and 2E (cell culture-derived)]. Consistent with earlier findings, 19 the majority of prostasomes were within a size range of 30-200 nm. Less than 3% (seminal) and 6% (cell) of the analyzed prostasomes had a diameter >200 nm. Real-time thrombin generation in plasma using the calibrated automated thrombography (CAT) method analyzed the procoagulant activity of seminal and cell culture prostasomes. Seminal (Fig. 2C ) and cell culture (Fig. 2F) prostasomes induced thrombin generation in a dose-dependent manner. Prostasomes shortened lag time and time to peak and increased maximal and total thrombin (endogenous thrombin potential, ETP). Prostasome-triggered thrombin formation was similar For personal use only. on September 14, 2017. by guest www.bloodjournal.org From in normal platelet-free and vesicle-depleted plasma. Deficiency in factors XII and XI and addition of the recombinant FXIIa-inhibitor rHA-Infestin-4 (Inf-4, 500 µg/ml) 15 to normal plasma significantly prolonged lag time and time to peak, and reduced peak and total thrombin activated with prostasomes (Fig. 2G, Table 1 ). Inhibition of TF activity with ASIS reduced peak and total thrombin, and prolonged time to peak and lag time more than Inf-4 addition. Prostasome-induced thrombin formation was more reduced in FXI-than in FXIIdeficient plasma (ETP: 568 ± 176 vs. 1098 ± 186 nM*min). In the absence of FXI, TFmediated thrombin generation is unable to amplify coagulation via the FXI feedback activation loop. 26 Combined application of Inf-4 and ASIS completely blunted prostasomeinduced procoagulant activity (Fig. 2H, Table 1 ). Consistent with thrombin formation assays, prostasomes initiated plasma clotting in a FXII-dependent manner (Fig. 2I) . Addition of Inf-4 prolonged prostasome-stimulated recalcification clotting time vs. buffer in ultracentrifuged normal plasma (NP) (766 ± 55 sec vs. 357 ± 35 sec, P< .001). In line, prostasome-initiated clotting was prolonged in plasma deficient in factors XII (594 ± 53 sec, P< .01 vs. NP) or XI (943 ± 31 sec, P< .001 vs. NP). Addition of ASIS to NP also interfered with prostasomeinduced clotting (546 ± 46 sec, P< .01 vs. NP). Combined application of Inf-4 and ASIS completely abolished prostasome-initiated fibrin formation (>1500 sec). The FXIIa/PK chromogenic substrate S-2302 confirmed that prostasomes dose-dependently initiated the contact system in NP (Fig. 2J) . Prostasome-induced S-2302 conversion was reduced to buffer levels in FXII deficient plasma (P> .05) and was largely diminished in the absence of PPK or HK (P< .05 vs. NP+Buffer, Fig. 2K ). Similarly to PC3 prostasomes, exosomes derived from pancreatic cancer (Panc1, BxPC3 and Capan2) and promyelocytic leukemia cells (HL-60) triggered S-2302 cleavage in a FXII dependent manner (Fig. 2L) .
Prostasome-and PC cell-derived polyP initiates fibrin formation via FXII activation
How do prostasomes and PC cells generate FXIIa? One possible candidate is the FXII contact activator polyP.
14, 15 We purified polyP from PC3 prostasomes ( Fig. 3A ) and PC3 cells (Fig. 3B) by anion affinity chromatography. Eluted material was separated by urea/acrylamide-gel electrophoresis and visualized by the polyP-sensitive DAPI-negative staining.
27 Prostasome and PC3 cell polyP migrated with similar heterodispersity and polymer chain length ranging from approximately 200 to >1000-mers. Treatment with phosphatase (Psp), which hydrolyzes polyP, completely abolished the signal. We used recombinant PPBD as a probe for polyP. PPBD specifically binds to polyP of chain length >35.
28 PolyP localized to the surface of prostasomes and co-localized with the prostasome cell-surface marker CD63 29 (Fig. 3C) . Treatment of prostasomes with Psp blunted PPBD binding (not shown). Similarly to prostasomes, polyP enriched at the plasma membranes of non-permeabilized PC3 cells (Fig. 3D) . PPBD detected cytoplasmic polyP in a spotty vesicular pattern in permeabilized PC3 cells (Fig. 3F) . We incubated prostasomes with human plasma and stained for FXIIa using Alexa 488-conjugated 3F7 antibody that specifically cross-reacts with the active enzyme but not with the zymogen form.
24 Plasma incubation led to FXIIa formation and the protease co-localized with polyP at the plasma membrane (Fig. 3E) . PolyP isolated from prostasomes ( Fig. 3G ) and PC3 cells (Fig. 3H ) stimulated S-2302 conversion in plasma. The polyP inhibitors PPBD (1 mg/ml), generation 1.0 cationic poly(amido amine) (PAMAM) dendrimer (25 µg/ml) and degradation of polyP with Psp (1 U/ml) abolished polyP-induced amidolytic activity. PolyP was inactive in FXII deficient plasma. Consistent with PC polyP-stimulated FXII formation, prostasome-( Fig. 3I ) and PC3 cell- (Fig. 3J ) polyP triggered thrombin formation in a FXII dependent manner and PPBD and generation 1.0 cationic PAMAM dendrimer blocked the procoagulant activity conferred by PC-derived polyP. To analyze the functions of PC-derived polyP in thrombosis, we injected WT mice i.v. with saline or PPBD (150 µg/g bw) 10 min prior to prostasome challenge (Fig.  3K) . PPBD significantly protected mice from lethal PE, whereas all saline-infused animals died within 30 min after challenge (3/5 vs. 0/5 mice survived, P< .05). We analyzed polyP on prostasome plasma membranes using a PPBD-based ELISA (Fig. 3L) . PolyP content decreased from PC3-over seminal-to patient plasma-derived prostasomes. PolyP content correlated with the procoagulant activity of prostasomes. We analyzed histological sections of human prostate adenocarcinoma for the procoagulant polyP/FXII pathway (Figs. 3M-P'). (Figs. 3N and 3N') . We probed for polyP and fibrin in PC tissue frozen sections as the water-soluble polyP gets lost during the deparaffinization procedure. PPBD showed polyP enriched in cancer glands and in stromal smooth muscle fibres (Figs. 3O and 3O') and 59D8 antibody visualized extravascular fibrin deposition at these sites (Figs. 3P and 3P') .
FXIIa inhibition provides safe protection from prostasome-induced lethal pulmonary embolism The fully humanized anti-FXIIa antibody 3F7 is a candidate future therapeutic agent, binds into the FXIIa enzymatic pocket and inhibits the amidolytic activity of the protease.
24 3F7 dose-dependently interfered with synthetic long chain polyP (LC polyP)-stimulated thrombin generation and antibody concentrations ≥ 375 nM completely abolished polyP-triggered coagulation in murine plasma (Fig. 4A) . To analyze the prophylactic application of 3F7 for interference with PC-mediated PE, we injected WT mice i.v. with saline or 3F7 (4.5 µg/g bw) 10 min prior to prostasome challenge (Fig. 4B) . 3F7 conferred significant protection (P< .001 vs. saline) from prostasome-induced PE (6/6 mice survived) whereas all saline-infused animals, with the exception of a single mouse, died within 30 min after challenge. Increased survival rate in 3F7-treated mice correlated with increased lung perfusion and less vascular occlusion compared to lungs of saline-treated animals (Fig. 4C) . Fibrin staining in histologic sections of lungs from saline-treated mice confirmed diffuse thrombotic occlusion, while fibrin deposition was significantly less (P< .001 vs. saline) in 3F7-infused animals ( Fig. 4D and  4E) . We determined the tail bleeding time and extent of bleeding (blood loss) by quantification of lost hemoglobin until cessation of bleeding as a measure of hemostatic capacity. 3F7 neither prolonged the bleeding time (270 ± 117 sec vs. 282 ± 148 sec, P> .05, 
Activation of FXII contributes to increased procoagulant activity of PC-derived plasma prostasomes
Thrombin generation was increased in plasma samples from PC patients (Suppl. Fig. 5D ) were significantly increased in patients over control. Depletion of vesicles abolished the procoagulant activity in patient plasma and reconstitution of the ultracentrifuged plasma samples with purified prostasomes restored their procoagulant activity. We analyzed the contribution of prostasome polyPgenerated FXIIa for procoagulant activity in PC patients. Prostasomes/exosomes isolated from plasma of 20 PC patients, 10 healthy male and 10 healthy female controls (Suppl. Table 2 ) triggered thrombin formation in normal plasma. Exosomes derived from female plasma exhibited procoagulant activity similar to that of healthy males (ETP: 938 ± 114 vs. 683 ± 121 nM*min, P> .05). For comparison we supplemented ultracentrifuged plasma with synthetic phospholipids. Procoagulant activity conferred by phospholipids alone was similar to those induced by healthy individuals (ETP: 1073 ± 106 nM*min, P> .05 vs. healthy males and females). The procoagulant activity of prostasomes from PC patients was significantly higher than those from healthy male controls. Lag time (25.1 ± 2.1 vs. 14.5 ± 1.1 min, P< .001, Fig. 5E ) and time to peak (32.0 ± 1.9 vs. 20.8 ± 1.3 min, P< .001, Fig. 5F ) were shortened by 42% and 35%, respectively, and maximum (39 ± 7 vs. 145 ± 14 nM, P< .001, Fig. 5G ) and total thrombin (683 ± 121 vs. 1763 ± 39 nM*min, P< .001, Fig. 5H ) were increased by 3.7-and 2.6-fold, respectively. Inhibition of FXIIa activity with 3F7 (100 µg/ml) significantly reduced the increased procoagulant activity of patient prostasomes. 
supplemented with prostasomes from PC patients. FXIIa inhibition similarly reduced procoagulant activity of patient-and cell culture-derived prostasomes (Fig. 2G, Table 1 , 38% ETP reduction each). Procoagulant activity of prostasomes isolated from PC patients with a history of thromboembolic disease was increased over samples from patients without previous vascular occlusive events (Suppl. Fig. 1) . Taken together, these data show a role of prostasome-generated FXIIa in the increased procoagulant activity seen in PC patients.
For
DISCUSSION
Malignancy has been associated with increased risk of thrombosis for more than a century.
31
The TF/factor VIIa pathway is believed to be the principal initiator of fibrin formation in cancer patients. 32 Cancer cells express TF on their plasma membrane 33 and release TF-bearing microparticles (MP) into the circulation. 34 MPs are procoagulant as they promote thrombus propagation in mouse models and trigger clotting in human plasma. 35 In Here, we show that particles derived from PC, pancreatic cancer as well as promyelocytic leukemia cells initiate coagulation in a FXII-dependent manner (Fig. 2) , triggered by exposure of polyP on their plasma membranes (Fig. 3) . These findings extend earlier studies showing that MPs derived from platelets of healthy individuals initiate coagulation via FXII activation. 44 Vice versa platelet-stimulated fibrin formation is defective in the absence of FXII.
45-47 Supporting a function for the polyP/FXII coagulation pathway in cancer-associated thrombosis, zymogen FXII plasma levels are low in samples from patients with advanced gastrointestinal 48 and non-metastatic colorectal cancer 49 compared to healthy controls. Furthermore, diminished plasma FXII is associated with reduced PPK levels and an increase in PK bound to its endogenous protease inhibitors in lung cancer patient plasma samples. 50 These observations suggest that polyP/FXII-initiated coagulation has implications in patients with PC and also in patients with other malignancies.
PolyP procoagulant activity increases with chain length 51 and polymers of <45 units do not support FXII contact activation. 15 Consistent with synthetic long chain polyP, 51 natural PCderived polyP (200 to >1000-mers) is a potent FXII contact activator (Fig. 3) . PolyP content exposed on the plasma membrane of various prostasomes varied and correlated with the procoagulant activity of these particles. There was a trend for higher polyP expression on prostasomes derived from PC patients with a history of thromboembolic disease, however, further studies are warranted to confirm this observation. In addition to initiating the FXIIadriven intrinsic pathway of coagulation, polyP accelerates multiple downstream procoagulant mechanisms including factor V and factor XI feedback activation, and blocks the anticoagulant activity of TF pathway inhibitor (TFPI). 16 The polyP/FXII pathway operates independently of TF-mediated coagulation 52 and also results in PK mediated release of the proinflammatory and vasodilatory peptide BK. 15 ,53 Therefore, targeting polyP using cationic proteins, polymers, or small molecules 54 may represent a promising strategy for interfering with cancer-driven coagulation and potentially, inflammatory reactions. 55 PolyP/FXII inhibition and deficiency in factors XI, XII or HK interfered with prostasome-induced lethal PE (Fig. 1) . Similar to infusion of pure polyP 56 and platelet stimulation, 57 injection of prostasomes induced microvascular PE. In humans, microvascular PE represents a complication of tumor cell embolism. [58] [59] [60] Klkb1 -/-mice died upon i.v. pure polyP infusion. 56 The animals were not protected from prostasome challenge either (Fig. 1) , supporting the presence of polyP on prostasomes. Infusion of polyP into Bdkrb2 -/-animals induced lethal PE 15 and consistently, the mice were also susceptible to prostasome-triggered PE. Although polyP initiates BK formation, i.v. prostasome infusion did not reduce systemic blood pressure. A plausible explanation is that formed BK is rapidly inactivated in the pulmonary microvasculature by For personal use only. on September 14, 2017. by guest www.bloodjournal.org From kinin-degrading enzymes before the mediator reaches pressure-regulating vessels. [61] [62] [63] [64] Our animal models and patient material data show that both TF/FVIIa and polyP/FXIIa pathways contribute to PC-associated hypercoagulable states. Thrombin formation in vitro was more reduced in TF-than in FXIIa-inhibited plasma (Fig. 2) , however, targeting each of the pathways was sufficient to protect mice from lethal PE in vivo (Fig. 1) . TF/FVIIa and polyP/FXIIa have distinct and differential functions in thrombus initiation and propagation. TF appears as the initiator of thrombosis on ruptured plaques, while FXIIa drives coagulation distant from the vessel wall within the propagating thrombus. 65 Indeed, inhibition of FXII activity interferes with mechanical thrombus stability in whole blood 15 and increases embolization rate in treated mice. 65 Emphasizing a role for FXII in thrombus growth, inherited deficiency or pharmacologic neutralization of the factor is sufficient to protect mice from TFtriggered lethal PE. 66 In cancer-related thrombosis, LMWH is the preferred mode of anticoagulation over VKAs (warfarin). 67 This recommendation is based on data showing decreased VTE recurrence with use of LMWH compared to VKAs. 68 In addition, VKA dosing in cancer patients is challenging as clinical studies indicated that the incidence of bleeding remains high even when INR values being close to or below 2.0. 69, 70 Bleeding complications are not restricted to VKA therapy as prospective randomized controlled trials comparing LMWH and VKA therapy in cancer-associated VTE have reported similar bleeding rates. 68 Data are insufficient to recommend the routine use of new oral anticoagulants as therapy for VTE in cancer patients. 71 Due to the potentially serious and life-threatening bleeding, all patients require an individualized assessment of their bleeding risk prior to the initiation of anticoagulation. Thus, there is need for effective anticoagulation strategies for patients with cancer. Targeting polyP/FXII interfered with the increased procoagulant activity in patient plasma (Fig. 5) and prevented PC-driven PE in mice without treatment-related risk of bleeding (Figs. 3 and 4) . Importantly, the decisive role of the intrinsic pathway of coagulation in thrombosis is not restricted to murine models. We have recently shown that the FXIIa-inhibitory antibody 3F7 offers a safe thromboprotective strategy in a preclinical setting.
24 3F7 blocks thrombosis as effectively as heparin in a cardiopulmonary bypass system in rabbits (ECMO system). However, in sharp contrast to heparin, 3F7 did not impair the hemostatic capacity of treated animals. Fully humanized 3F7 antibody has an immediate anticoagulant effect and is thus suitable for management of VTE in an acute setting. 24 Humanized antibodies expressed in mammalian cells are an important class of human therapeutic products and are expected to display minimal immunogenic potential in humans. 72, 73 An alternative method to interfere with FXII function is the use of antisense oligonucleotides (ASO) that knockdown FXII expression and confers protection from thrombosis without an increase in therapy-associated bleeding. 74, 75 Furthermore, lowering FXI levels with FXI-ASO reduced the rate of postoperative thrombosis and was safe with respect to bleeding risk in patients. 76 A disadvantage of this approach, however, is the long lag time in achieving therapeutic levels of anticoagulation (injections required 1-3 times weekly for 5 weeks). Currently, small molecule FXIIa inhibitors are under development with potential anticoagulant and additional anti-inflammatory activities.
In summary, the current study identifies a novel procoagulant mechanism driven by long chain polyP on PC cells and prostasomes that contributes to clotting in patient plasma in vitro and PE in mouse models in vivo. Interference with the polyP/FXII pathway provides a new approach for anticoagulation in PC-associated thrombosis that lacks the bleeding risk of currently used anticoagulants. 
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